Loading stock data…
$2.84-0.20 (-6.58%)
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.
SAB Biotherapeutics, Inc. in the Healthcare sector is trading at $2.84 with a market capitalization of $308M. Wall Street consensus targets $11.64 (11 analysts), implying a +309.7% move over the next 12 months. The stock is currently near its 52-week low of $2.44, remaining 23.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$23.38M↓ | -$20.00M↓ | -$15.77M↓ | -$12.68M↓ | -$9.73M |
| Net Income | -$22.49M↓ | -$18.87M↓ | -$16.86M↓ | $45.45M↑ | -$10.11M |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candi...